Clinical trials: High Risk Localized Prostate Cancer, active
Prostate Cancer
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
The purpose of this study is to test if treatment with medications that reduce the male hormone level in the participant's body for a few months before surgery can shrink prostate cancer as much as possible, which might reduce…
- Trial name
- NCT03436654
- Testing
- Apalutamide, Abiraterone Acetate, Prednisone
- Where
- 11 sites in United States
- Volunteers
- 102 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
High-intensity Focused Ultrasound Combined With Novel Hormone Therapy in Advanced Prostate Cancer
The goal of this clinical trial is to explore the feasibility and the synergistic anti-cancer effect of high-intensity focused ultrasound (HIFU) combined with novel hormone therapy (NHT) in advanced prostate cancer (PCa).
- Trial name
- HIFU NHT PCa (NCT07126093)
- Testing
- focal high-intensity focused ultrasound therapy combined with standard novel hormonal therapy, Standard novel hormonal therapy only
- Volunteers
- 134 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Prostate Cancer
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer
The primary objective of the trial is to assess if GnRH antagonists in combination with external beam radiation therapy improve progression free survival (progression that can be biological, clinical, or death) compared to GnRH…
- Trial name
- PEGASUS (NCT02799706)
- Testing
- Degarelix, approved GnRH agonist, Radiotherapy
- Where
- 39 sites in Belgium, Denmark and 6 more
- Volunteers
- 885 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00430183
- Testing
- docetaxel, LHRH agonist, surgery
- Where
- 226 sites in United States, Canada
- Volunteers
- 788 people
- Sponsor
- Alliance for Clinical Trials in Oncology
High-Risk Localized Prostate Cancer
PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT
This research is being done to find out if the study drug, 177Lu-PSMA-617, given before and during standard of care External Beam Radiation Therapy (EBRT) treatment, with a shorter course of Androgen Deprivation Therapy (ADT) (6…
- Trial name
- NCT07550517
- Testing
- EBRT + 6 mo ADT + 177Lu-PSMA-617, EBRT + 24 mo ADT
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
HDR Focal: Feasibility Study
Brachytherapy as a monotherapy treatment is highly effective for localized prostate cancer, traditionally being delivered to the whole prostate gland.
- Trial name
- NCT02918253
- Testing
- targeted focal HDR brachytherapy, Whole-gland HDR Brachytherapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University Health Network, Toronto
Localized Prostate Cancer
Clinical Study of HIFU for Localized Prostate Cancer
In this study, the safety and effectiveness data of Sonablate system, a transrectal high-intensity focused ultrasound therapeutic instrument, in the treatment of localized prostate cancer were collected, and the treatment…
- Trial name
- HIFU (NCT06362577)
- Testing
- EQ-5D-5L IPSS IIEF-5 EPIC-26 ECOG
- Where
- China
- Volunteers
- 60 people
- Sponsor
- RenJi Hospital
Prostatic Neoplasms
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
The purpose of this study is to determine the effectiveness of enzalutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinizing hormone releasing hormone analogue (LHRHA) in men having radiation therapy for…
- Trial name
- ENZARAD (NCT02446444)
- Testing
- Enzalutamide, Conventional NSAA, LHRHA
- Where
- 69 sites in United States, Australia and 7 more
- Volunteers
- 802 people
- Sponsor
- University of Sydney
Prostate Cancer
Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer
This is a two-Parallel cohort, prospective study, aimed to explore Efficacy and safety of neoadjuvant Darolutamide with or without ADT in high-risk/very high-risk localized-stage prostate cancer.
- Trial name
- ANDARP (NCT07476677)
- Testing
- Darolutamide, Darolutamide combined with ADT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Prostate Cancer
Registry for Prostate Cancer Focal Therapy
Whole gland therapy (radical prostatectomy and radiotherapy) has been the conventional treatment for localized prostate cancer, but randomized controlled trials have not demonstrated survival benefits compared with watchful…
- Trial name
- NCT07792590
- Testing
- Focal Therapy for Prostate Cancer
- Where
- Hong Kong
- Volunteers
- 200 people
- Sponsor
- The University of Hong Kong
Prostate Cancer
Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer
A prospective, multi-center, single-arm study, planned in 150 patients. The primary objective of the study is to further evaluate the safety and efficacy of a magnetic resonance imaging (MRI)-guided transurethral ultrasound…
- Trial name
- TACT (NCT02766543)
- Testing
- MRI-guided Transurethral Ultrasound Ablation
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 150 people
- Sponsor
- Profound Medical Inc.
Prostate Cancer, Radiation Therapy
Adjuvant Chemotherapy for High Malignant Prostate Cancer
This study aims to evaluate the efficacy of adjuvant docetaxel chemotherapy following radical radiotherapy in patients with localized high-grade prostate cancer.
- Conditions
- Prostate Cancer, Radiation Therapy, Chemotherapy, Gleason Score
- Trial name
- PKUFH-GS5 (NCT06864533)
- Testing
- Docetaxel
- Where
- 3 sites in China
- Volunteers
- 315 people
- Sponsor
- Peking University First Hospital
Prostate Cancer
Active Surveillance Plus (AS+): High-intensity Focused Ultrasound (HIFU) in Patients With Localized Prostate Cancer
PSA (Prostate-specific antigen) testing has significantly increased the number of men diagnosed with prostate cancer (PCa) and especially patients with low and intermediate risk disease.
- Trial name
- NCT04549688
- Testing
- high-intensity focused ultrasound, HIFU
- Where
- Norway
- Volunteers
- 250 people
- Sponsor
- The Hospital of Vestfold
Adenocarcinoma of the Prostate
Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients With Prostate Adenocarcinoma
Stereotaxic prostatic radiotherapy on Linac MRI, with monitoring of movements of the pelvic organs per fraction on the prostate in real time, in 4 sessions, with integrated boost on the index tumor (if it is visible on the…
- Trial name
- STEREO-RML (NCT04909294)
- Testing
- Stereotactic Radiotherapy with Linac MRI
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Centre Georges Francois Leclerc
Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy
Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer
This study is for adult men with previously untreated high risk, very high risk, or pelvic lymph node positive prostate cancer. The purpose of this study is to evaluate the safety and effectiveness of the combination of two…
- Trial name
- NCT07325721
- Testing
- Hypofractionated radiation with a microboost
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Medical University of South Carolina
High Risk Localized Prostate Cancer, Synchronous Metastatic Hormone-Sensitive Prostate Cancer
Prospective Prostate Cancer Infrastructure
The goal of this observational study is to collect detailed long-term real-world data and biomaterials from men with high-risk localized prostate cancer and synchronous metastatic hormone-sensitive prostate cancer.
- Trial name
- ProPCI (NCT07560748)
- Where
- Netherlands
- Volunteers
- 700 people
- Sponsor
- Radboud University Medical Center
Prostate Cancer Patients Undergoing External Radiation and Seed Implantation, High Risk Localised Prostate Carcinoma
Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions
Every year, about 700 Danish men get radiotherapy for prostate cancer with a high-risk of later progression. The risk of relapse is about 40 % after 5 - 8 years, so we need better treatment for these patients in Denmark and…
- Conditions
- Prostate Cancer Patients Undergoing External Radiation and Seed Implantation, High Risk Localised Prostate Carcinoma, Locally Advanced Prostate Cancer, Unfavourable Intermediate Risk Prostate Cancer
- Trial name
- DAPROCA10 (NCT07343349)
- Testing
- Addition of focal boost and hypofractionation
- Where
- 3 sites in Denmark
- Volunteers
- 1,016 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Prostate Cancer, Prostate Adenocarcinoma
A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer
Men with localized, intermediate risk prostate cancer will be randomized to undergo either radical prostatectomy or the TULSA procedure, with a follow-up of 10 years in this multi-centered randomized control trial.
- Trial name
- CAPTAIN (NCT05027477)
- Testing
- Radical Prostatectomy, TULSA Procedure
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 201 people
- Sponsor
- Profound Medical Inc.
Prostate Cancer
Clinical Data Collection of Patients Treated With High Intensity Focused Ultrasound (HIFU) by the Focal One for Their Prostate Cancer.
The aim of the registry is to gather real-life data to evaluate the clinical performance and safety of medical devices in patients who have been treated with HIFU thank to the Focal One device for their prostate cancer.
- Trial name
- One registry (NCT07645872)
- Where
- 5 sites in France
- Volunteers
- 3,000 people
- Sponsor
- EDAP TMS S.A.
Prostate Cancer, Prostate Cancer (Diagnosis)
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy.
- Conditions
- Prostate Cancer, Prostate Cancer (Diagnosis), High-risk Prostate Cancer, Localized Prostate Carcinoma
- Trial name
- LUTACT (NCT07054346)
- Testing
- 177 Lutetium Prostate-Specific Membrane Antigen 617, Actinium-225 Prostate-Specific Membrane Antigen 617, Non-investigational, Prostatectomy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Thomas Hope